Zhimeng Biopharma Completes Enrollment for ALS Clinical Trial

Shanghai Zhimeng Biopharma has completed patient enrollment for its pivotal Phase 2/3 clinical trial of CB03-154, an investigational drug for amyotrophic lateral sclerosis (ALS). A total of 255 patients are now participating in the study, which evaluates the efficacy and safety of this next-generation potassium channel opener. This milestone is crucial for the drug's development in China, paving the way for future data analysis and potential regulatory submissions for a debilitating neurodegenerative disease.